Solutions for Detection of Apoptosis in Oncology Xenograft Models
At DiaPharma, we specialize in biomarker assays designed to advance oncology research. One of the hallmarks of cancer is the evasion of apoptosis by tumor cells—making the detection of cellular death, especially apoptosis, a critical readout in the evaluation of anti-cancer therapies.
Xenograft models are widely used in oncology research to study cancer therapies in vivo. However, methods for evaluating the effect of potential drug candidates on tumor growth—such as volume measurements, imaging, or immunohistochemical staining—are often imprecise, expensive, technically demanding, or require sacrificing the xenograft host.
This blood-based biomarker assay utilizes the M30® antibody which specifically detects a caspase-cleaved fragment of cytokeratin 18 (CK18), a cytoskeletal protein expressed in epithelial cells and cleaved by caspases early during apoptosis. The cleaved CK18 fragment (ccK18) is released into the bloodstream, and its concentration in serum or plasma measured with the M30 Apoptosense® ELISA correlates with the extent of epithelial cell apoptosis.
Why choose the M30 Apoptosense® ELISA for use with your xenograft model?
● The M30® antibody is highly specific for human ccK18 and does not cross-react with murine proteins, enabling precise detection of apoptosis of human tumor cells with xenograft models.
● Minimally invasive blood sampling allows for longitudinal assessment of treatment response.
● The assay provides sensitive, quantitative measurements to evaluate dose- and time-dependent effects of potential drug candidates.
● Incorporating the M30® biomarker offers a robust, translational tool to strengthen efficacy assessments — particularly valuable for bridging preclinical findings to clinical applications.
We would be happy to provide more detailed information tailored to your research. Please don’t hesitate to reach out to our Scientists or your local DiaPharma Territory Manager.
*For research use only in US and Canada. Not for use in diagnostic procedures.
It’s Not Just Support. It’s Solutions. T-TAS 01®: ex vivo measurement of thrombus formation with a simple flow chamber system We invite you to an online seminar: T-TAS® 01: ex vivo measurement of thrombus formation with a simple flow chamber system This online seminar provides the fundamental explanations for T-TAS (Total Thrombus-formation Analysis System) including…
It’s Not Just Support. It’s Solutions. One Week in Bangkok: Reflections on ISTH 2024 Our Scientific Director, Jennifer J. Kiblinger, and Director of Commercial Operations, Gloria Sukes O’Neill, traveled to Bangkok for the The International Society on Thrombosis and Haemostasis (ISTH) 2024 Congress in June to hear from the world’s leading minds in thrombosis and…
Jennifer J. Kiblinger Scientific Director First, I need to comment how amazing the people of Thailand were. This introvert was a bit worried about going to such a crowded city, but everyone was so hospitable. At the hotel, at the convention center, on the public transit. Those of you who stayed to the end perhaps…
It’s Not Just Support. It’s Solutions. View the Webinar Recording Breaking Barriers: The Evolution of ADAMTS13 Testing Everyone loves a good historical perspective talk! Dr. Gary Moore really delivers one here about TTP and ADAMTS13 activity, with a good bit of technology comparison to boot. If you missed the webinar, no worries. You can view…
It’s Not Just Support. It’s Solutions. Exploring Unmet Needs in Islet Cell Transplantation and Stem Cell-Derived Islet Research DiaPharma’s Dr. Abi Kasberg headed to Florence for the 2024 Advanced Technologies & Treatments for Diabetes (ATTD) conference to learn more about the utility of intact proinsulin as a biomarker in diabetes and how new drugs in…
It’s Not Just Support. It’s Solutions. Complimentary Webinar Breaking Barriers: The Evolution of ADAMTS13 Testing Thursday, June 6 1:00 PM EDT Please join DiaPharma, our partner Technoclone for a webinar presented by Professor Gary Moore, about TTP, TMAs, and the “value add” of laboratory testing for ADAMTS13 activity. We will discuss the significance of ADAMTS13,…
It’s Not Just Support. It’s Solutions. T-TAS 01 in Thailand! DiaPharma is excited to share that ZACROS, manufacturer of the T-TAS 01, will be exhibiting at ISTH 2024 in Booth #1609. During the exhibition, there will be an opportunity to see T-TAS 01 demonstrations and discuss applications for the clinical laboratory. We invite DiaPharma customers…
It’s Not Just Support. It’s Solutions. Complimentary Webinar Breaking Barriers: The Evolution of ADAMTS13 Testing Thursday, June 6 1:00 PM EDT Please join DiaPharma, our partner Technoclone for a webinar presented by Professor Gary Moore, about TTP, TMAs, and the “value add” of laboratory testing for ADAMTS13 activity. We will discuss the significance of ADAMTS13,…
David L. McGlasson, MS, MLS(ASCP) Several years ago, I was the lead author of a manuscript titled: Comparison of six dilute Russell Viper Venom Time (DRVVT) lupus anticoagulant (LA) screen/confirm assay kits.1 The purpose of the protocol was to see if using normalized ratio gave our laboratory any better inter-method consistency when performing the DRVVT…
It’s Not Just Support. It’s Solutions. Complimentary Webinar ATLAS Platelet Strength Test: A New Dimension in Platelet Function Wednesday, May 22 at 1 p.m. EDT The newest way to correlate platelet strength and size with functionality DiaPharma is excited to invite you to a webinar where we will delve into the innovative ATLAS PST…
-Contributed by Abi Kasberg, PhD Attending my first Advanced Technologies & Treatments for Diabetes (ATTD) conference in Florence, Italy this March was a treat for the mind (and palate). Being new to the diabetes space, it was thrilling to learn about the latest insights and advancements that are being made in diabetes research to improve…
It’s Not Just Support. It’s Solutions. TECHNOZYM ADAMTS13 ACTIVITY KIT DiaPharma is pleased to offer the first in vitro diagnostic (IVD) test to receive marketing authorization by the FDA. The Technozym ADAMTS13 Activity assay is an enzyme-linked immunosorbent assay (ELISA) intended for the qualitative determination of ADAMTS13 activity in platelet poor human citrated plasma. The…
It’s Not Just Support. It’s Solutions. You’re Invited: Complimentary Webinar CK18 – the Key to Unlocking Informed Decisions in MASH Drug Trials Are the Arrows Pointing in the Right Direction? CK18 Biomarkers Can Provide Insight into Your MASH Drug Candidate’s Future Success Tuesday, April 23 at 1 pm EDT When: Tuesday, April 23 at 1…
It’s Not Just Support. It’s Solutions. Balancing Platelet Strength & Function with the Stasys Atlas PST Atlas PST detects all mechanisms of platelet dysfunction in less than 3 minutes. Global assay of primary hemostatic potential Whole blood specimen for rapid analysis (< 3 minutes) Uniquely measures platelet contractile forces, aggregation, and function Reagents and agonists…
It’s Not Just Support. It’s Solutions. Technozym ADAMTS13 Activity granted marketing authorization by the FDA DiaPharma and Technoclone are pleased to announce the FDA De Novo classification grant and authorization to market the first in vitro diagnostic (IVD) assay for the qualitative determination of ADAMTS13 activity. The Technozym ADAMTS13 Activity assay is an enzyme-linked immunosorbent…
It’s Not Just Support. It’s Solutions. How can blood-based biomarkers enrich your Type 1 Diabetes (T1D) study population? TECO® Intact Proinsulin ELISA When it comes to measuring pancreatic Beta cell function, go with the Pro! Save time and guess work by selectively measuring only intact proinsulin. Intact Proinsulin is produced by beta-cells (β-cells) in…
It’s Not Just Support. It’s Solutions. Measuring Warfarin in Patients with a Lupus Anticoagulant Throughout last year, the use of DOACs in patients with antiphospholipid antibody syndrome (aPS) has been debated. Here we address two key questions: What are the options for monitoring a patient with the presence of a strong LA inhibitor, where INRs…
It’s Not Just Support. It’s Solutions. Register today for Nothing but NETs: Unraveling biomarkers for NETosis research A webinar aimed to examine widely used biomarkers of NETosis, and understanding how they can best used to paint a complete picture of relevant events in disease. This presentation hopes to highlight commonly used assays, while introducing Volition’s…
David L. McGlasson, MS, MLS(ASCP) A few months ago, I posted on LinkedIn that I noticed at recent conferences and journal articles that blood coagulation factors were sometimes referred to in Euro-Arabic numbers (E-A), 0 through 9, instead of Roman numerals.For example, “F8” was written instead of “FVIII”.And sometimes they are used interchangeably. I received…
-Contributed by Abi Kasberg, PhD Changes have arrived to the field of hepatic steatosis! In efforts to destigmatize and enhance the identification of steatotic liver diseases, several worldwide governing bodies (AASLD, EASL, and ALEH) recently came together to form a multi-stage Delphi panel that assessed, edited, and published changes to the standard nomenclature and diagnostic…
